Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
UNICANCER
Thomas Jefferson University
Fudan University
University of Vermont
Fundación GECP
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
Mayo Clinic
Sun Yat-sen University
University of Southern California
Weill Medical College of Cornell University
Gustave Roussy, Cancer Campus, Grand Paris
Ohio State University Comprehensive Cancer Center
Peking University Cancer Hospital & Institute
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Chest Hospital
Stanford University
Fundación GECP
Fundación GECP
Tianjin Medical University Cancer Institute and Hospital
Spanish Lung Cancer Group
M.D. Anderson Cancer Center
Goethe University
Sichuan University
Tianjin Medical University Cancer Institute and Hospital
The Netherlands Cancer Institute
Hunan Province Tumor Hospital
Spanish Lung Cancer Group
Memorial Sloan Kettering Cancer Center
Aetion, Inc.
Aetion, Inc.
Shanghai Junshi Bioscience Co., Ltd.
M.D. Anderson Cancer Center
Tang-Du Hospital
Shanghai Chest Hospital
Hunan Province Tumor Hospital
M.D. Anderson Cancer Center
Shanghai Jiao Tong University School of Medicine
The Affiliated Hospital of Qingdao University
Spanish Lung Cancer Group
Sun Yat-sen University
Emory University
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
Nanfang Hospital, Southern Medical University
Samsung Medical Center
Peking Union Medical College Hospital
National Cancer Institute, Naples